patient selection for pembrolizumab in hnscc
Published 7 years ago • 433 plays • Length 5:01Download video MP4
Download video MP3
Similar videos
-
5:34
pembrolizumab for recurrent hnscc
-
5:56
patient selection in treating hnscc
-
4:35
patient selection for nivolumab in hnscc
-
11:47
pembrolizumab in hnscc
-
0:40
dr. vokes on selecting nivolumab or pembrolizumab for head and neck cancer treatment
-
1:35
dr kirtane on an investigation of tils plus pembrolizumab in advanced hnscc
-
6:51
pembrolizumab and nivolumab in recurrent hnscc
-
3:15
phase ii study of petosemtamab and pembrolizumab for recurrent/metastatic hnscc
-
1:52
dr. burtness on promise of frontline pembrolizumab in metastatic hnscc
-
1:23
dr. burtness on the benefit of pembrolizumab in head and neck cancer
-
3:55
checkpoint inhibitors for recurrent hnscc
-
1:41
dr. bauml on keynote-055 study for patients with hnscc
-
1:44
dr. ferris on impact of fda approval of pembrolizumab in patients with head and neck cancer
-
1:36
dr. seiwert on prognosis for patients with head and neck cancer
-
0:51
dr. machiels on pembrolizumab and chemoradiation in hnscc
-
5:22
new therapies for hnscc
-
33:50
immunotherapy for recurrent or metastatic hnscc: what are the practical considerations?
-
3:47
pembrolizumab as treatment for oligometastatic nsclc
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer